| Ticker | STRO |
|---|---|
| ISIN | US8693672011 |
| Sector | Tecnología |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | $294.790.208 |
| Beta | 1,31 |
| Sitio web | https://www.sutrobio.com |
| CEO | Jane Chung |
| Fecha de IPO | 27/09/2018 |
| País | US |
| Dirección | 111 Oyster Point Boulevard, South San Francisco, CA, 94080 |
| Volumen | 188.818 |
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical tri...
Sutro Biopharma, Inc opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones